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Is 1251 iothalamate an ideal marker for glomerular filtration? The
triiodinated angiographic contrast medium, iothalamate, has (usually
labelled 1251) been used extensively as a marker for glomerular filtration.
We have studied the renal handling of 125J iothalamate (lOT) in viva and
in vitro in several species. In renal cortical slices from chicken, rabbit,
rat, and monkey, the tissue-to-medium ratio of JOT was twice that of
51Cr-EDTA (EDTA) at 37°C; a difference that was abolished at 0°C and
markedly reduced by added o-iodohippurate or iodipamide. In five
chickens the steady-state renal clearance of JOT (CloT) was twice (P <
0.05) that of EDTA (CEDTA) or 3H inulin (C1); a difference that was
abolished by administration of 100 mg/kg/hr of novobiocin, an organic
anion transport inhibitor. CEDTA was similar to C1 before as well as after
transport inhibition. Utilizing the Sperber technique the mean apparent
tubular excretion fraction (ATEF) of JOT was 8%, while that of EDTA
was 1% (P < 0.01; N = 10). After novobiocin coinfusion (new
steady-state) ATEFIOT was significantly reduced (P < 0.01) and not
different from that of EDTA (— 1%). In the same animals the total
urinary recovery of lOT was 84 and 57% (P < 0.01) before and after
novobiocin, respectively, while corresponding values for EDTA was
unchanged by the inhibitor. In seven rats the renal extraction of JOT
was reduced from 29 to 17% (P < 0.05) by coinfusion of probenecid (5
mg/kg/hr). Corresponding extractions were 82 to 34% (P < 0.005) and
22% (unchanged) for PAH and EDTA, respectively. In six healthy
volunteers the renal clearance of unlabelled JOT (HPLC method)
equated that of creatinine but exceeded that of inulin with 38% (P <
0.01). This difference was reduced 34% (P < 0.05) by probenecid (1 g
i.v.). In nineteen patients with a single or two kidneys the average
plasma clearance (single injection technique; slope-intercept method) of
JOT was 13% higher than that of EDTA(P <0.001); a difference which
was significantly (P < 0.01) reduced to half after pretreatment with
probenecid (1 g i.v.); in some patients this difference was marked. The
results show that lOT is subject to a significant and in some cases
marked renal tubular secretion in chicken, rats, and humans. JOT,
therefore, is not an ideal marker for glomerular filtration.
Le 1251 iothalamate est-il un marqueur ideal de Ia filtration
glomérulaire? L'iothalamate, un produit de contraste angiographique
tri-iodé a été largement utilisé (habituellement marqud a 1251) comme
marqueur de Ia filtration glomérulaire. Nous avons étudié l'excrétion
rénale du 125J iothalamate (JOT) in vivo et in vitro dans différentes
espèces. Dans des tranches corticales de rein de poulet, de lapin, de rat,
et de singe, le rapport tissu sur milieu de l'IOT était le double de celui
du 51Cr-EDTA (EDTA) a 37°C; une difference abolie a 0°C et réduite de
facon marquee par l'addition de O-iodohippurate ou d'iodipamide.
Chez cinq poulets Ia clearance rénale a l'equilibre d'IOT (CloT) était le
double (P < 0,05) de celle de 1'EDTA (CEOTA) ou de 3H inuline (C1); une
difference abolie par l'administration de 100 mg/kg/hr de novobiocine,
un inhibiteur du transport des anions organiques. CEI)TA était identique
a C avant comme aprés l'inhibition du transport. En utilisant la
technique de Sperber, Ia fraction d'excrétion tubulaire apparente
moyenne (ATEF) de l'JOT était de 8%, alors que celle de I'EDTA était
de 1% (p < 0,01; N = 10). Après coperfusion de novobiocine (nouvel
equilibre) ATEFIOT était significativement réduite (P < 0,01) et non
différente de celle de l'EDTA (— 1%). Chez les mémes animaux, la
récupération urinaire totale d'IOT était de 84 et 57% (P < 0,01) avant et
aprés novobiocine, respectivement, alors que les valeurs cor-
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respondantes pour I'EDTA étaient inchangees par l'inhibiteur. Chez
sept rats, l'extraction rénale d'IOT était réduite de 29 a 17% (P < 0,05)
par coperfusion de probénecide (5 mg/kg/hr). Les extractions cor-
respondant étaient de 82 a 34% (P < 0,005) et de 22% (inchangees) pour
le PAH et l'EDTA, respectivement. Chez six volontaires sains, Ia
clearance rénale de l'IOT non marqué (méthode HPLC) était egale a
celle de Ia créatinine mais dépassait celle de l'inuline de 38% (P < 0,01).
Cette difference était réduite de 34% (P < 0,05) par Ic probenécide (1 g
iv.). Chez dix-neuf malades avec un ou deux reins, Ia clearance
plasmatique moyenne (technique par injection unique; méthode
d'interception de Ia courbe) de l'JOT était 13% plus élevée que celle de
I'EDTA (P < 0,01); une difference qui était significativement (P < 0,01)
réduite de moitié après prétraitement par le probenecide (1 g i.v.); chez
certains malades cette difference était marquee. Ces résultats montrent
que l'JOT est sujet a une sécrétion tubulaire rénale significative et
parfois marquee chez Ic poulet, Ic rat, et l'homme. L'IOT n'est done
pas un marqueur ideal de la filtration glomerulaire.
Since the renal clearance concept was developed by Homer
Smith [1], monitoring the glomerular filtration has played a
central role in renal physiology and clinical nephrology. An
ideal marker for glomerular filtration should be metabolically
inert, non-toxic, and should not alter the renal function. Fur-
thermore, it should be freely filtrable, not bound to plasma
proteins or blood cells and, of course, it should neither be
reabsorbed nor secreted by the renal tubules. Inulin is the
classic marker for glomerular filtration 2J whether analyzed by
chemical or radioactive methods. Presently, however, other
radioactive tracers are usually preferred. The tracers available
are 5tCr-labelled EDTA (ethylene diamine tetraacetic acid),
Tc-labelled DTPA (diethylene triamine pentaacetic acid),
and iodine-labelled diatrizoate and iothalamate (Fig. 1). In
preliminary studies in our laboratory we used the Sperber
technique and found that renal clearance values for iothalamate
were higher than those expected. This prompted us to investi-
gate further the renal handling of iothalamate versus that of
other markers for glomerular filtration in the Sperber prepara-
tion, in rats and in healthy volunteers and in patients with a
single kidney or two kidneys. We also studied the in vitro
accumulation of iothalamate and 5tCr-EDTA in renal cortical
slices from several species. Our results unequivocally demon-
strate an active tubular secretion and perhaps also reabsorption
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of iothalamate, which therefore is considered unsuitable as an
ideal marker for glomerular filtration.
Methods
Studies with renal cortical slices
The in vitro accumulation of l25J iothalamate and 51Cr-EDTA
in renal cortical slices from chicken (N = 2), rabbit (N = 2), rat(N = 3), and cynomolgus monkey (N = 1) was studied, using
the technique previously described by Bárány [3, 4].
The tissue-to-incubation medium (T/M) ratio was calculated
from results in experiments at 0°C (ice) and at 37°C without and
in the presence of the transport competitive inhibitors sodium-
o-iodohippurate (l0- or 10-2 M) and iodipamide (l0- or 10-2
M), respectively.
Experiments with the Sperber technique
Five Rhode Island Red hens were used in clearance experi-
ments using a similar technique as described earlier [51. This
technique enables urine to be collected separately from the two
kidneys through plastic funnel cones sewn over each ureteral
opening. Tracer amounts of 1251 iothalamate, 51Cr-EDTA, and
3H-inulin were continuously infused via a polyethylene catheter
(PP 50) into the right (ipsilateral) medial tarsal vein, that is, at
least in part into the right renal portal system [51. One hour was
allowed to obtain steady-state conditions. Blood samples (0.5 to
0.8 ml) were then drawn from a polyethylene catheter (PP 50)
placed into the left (contralateral) medial tarsal vein in the
middle of each 10-mm clearance period and centrifuged im-
mediately.
After six 10-mm clearance periods in steady-state, sodium
novobiocin (100 mg/kg body weight and hour) was
coadministered for another six 10-mm periods via a poly-
ethylene catheter (PP 50) placed into the left brachial vein.
The above procedure allows calculation of the clearance of
each marker by the left (contralateral) kidney before and after
the inhibition of organic anion transport, because the blood
samples should give the systemic concentration of each sub-
stance, which is presented to this kidney by the arterial and the
renal portal circulations [5].
In the above five animals and in an additional five animals the
renal portal infusion of 1251 iothalamate allowed the apparent
tubular excretion fraction (ATEF) to be calculated as the
difference between 125j activity excreted into the urine on the
ipsilateral (right) and contralateral (left) side, respectively,
divided by the amount infused [5]. 51Cr-EDTA was used as the
control marker. In four separate experiments only the free 1251
isotope was administered. The effect ofnovobiocin coadministra-
tion (as above) was determined in all experiments.
Experiments with rats
The renal handling of 125J iothalamate was also investigated in
seven rats, which was done by measuring the extraction of 1251
iothalamate as well as that of '4C PAH and 51Cr-EDTA before
and during treatment with probenecid. A Sprague-Dawley
strain (Anticimex, Stockholm, Sweden) of rats was used. The
rats, each weighing 300 to 370 g, were kept on an Ewos standard
rat diet (Södertalje, Sweden) and water ad libitum until the day
of the experiment. Anesthesia was induced by an intraperi-
toneal injection of mactin® at a dose of 120 mg/kg body wt. The
body temperature was kept at 37.5°C through a servo-controlled
heating table. The left kidney was reached by a flank incision.
The renal vein was first perforated with a needle instrument and
a fibrin membrane-covered hole was formed. A polyethylene
catheter was then introduced through this hole without any
ligatures. The left renal ureter and the bladder were catheter-
ized; the bladder was catheterized only for drainage of the right
kidney. The femoral vein and artery were cannulated for
infusion and specimen sampling, respectively. The rats were
continuously infused with a Ringer solution (150 mM/liter NaCI
and 10 mM/liter NaHCO3) at a rate of 3 ml/kg body wt per hour.
125j iothalamate, '4C PAH, and 51Cr-EDTA were added to the
solution to give a concentration of 2, 5, and 2 Ci/ml, respec-
tively. When probenecid was given, it was added into the
infusion solution and administered at a rate of 50 mg/kg body wt
and hour.
The rats were allowed to equilibrate for 45 mm, whereafter
double clearance periods of 20 mm were started. The means
from these periods were used to calculate the extraction values.
Study in healthy volunteers
Six healthy males volunteered for a renal clearance study
with 30-mm urinary collection periods and spontaneous void-
ing. They drank water and soft drinks ad libitum which kept
urine volumes to 200 to 450 ml/30 mm. After a bolus injection of
50 mg/kg inulin and 100 mg sodium iothalamate, a continuous
intravenous infusion of 28 mg/mm and 1.5 mg/mm, respectively,
was administered through an indwelling cannula in one brachial
vein, Two hours were allowed to achieve a steady-state. Three
30-mm clearance periods were then performed before and after
the intravenous injection of 1 g probenecid (injection time, 5 to
40 mm), respectively. Blood samples were drawn from a
cannula placed in the opposite brachial vein. Plasma and urine
samples were analyzed for inulin (spectrophotometric method),
iothalamate (using the HPLC method of Boschi and Marchesini
[61), and creatinine (according to Jaffe).
Clinical study
The glomerular filtration rate (GFR) was also measured on 23
occasions in 19 patients with different degrees of stable renal
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Fig. 1. Chemical Structure of iothalamic acid. In diatrizoate and
iodamide CONHCH3 at position three is substituted by NHCOCH and
CH2NHCOCH3, respectively.
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Table 1. Simultaneously determined renal clearance of 51Cr EDTA
(CEDTA) and 125j iothalamate (CloT) and the difference between them
() in patients without and after probenecid pretreatment
Patient
Without
probenecid
After probenecid
no. Diagnosis
CEDTA ClOT
CEDTA CloT
Group I
1 Donor 93 104 11
2 Hydronephrosis 97 111 14
3
4
Arteriolar
thrombosis
Hypernephroma
63 79
123 136
16
13
5 Donor 96 108 12
6 Renal tumor 63 65 2
7 Donor 59 66 7
8 TBC 57 68 11
9 Donor 85 91 6
10 Donor 90 95 5
11 Hypernephroma 132 142 10
Group 2
12 Diabetes mellitus 25 34 9
13 Diabetes insipidus 99 131 32 103 104 1
14 Glomerulonephritis 61 63 2
15 Glomerulonephritis 123 130 7 126 139 13
16 Glomerulonephritis 76 87 11 95 94 —1
17 IgA nephropathy 124 132 8 96 100 4
18 SLE 37 47 10
19 Glomerulonephritis 137 139 2
functional impairment (see Table 1). Eleven patients had uni-
lateral nephrectomies more than 1 year prior to the present
investigation, and 12 patients were pretreated with probenecid
(1 g) intravenously 1 to 2 hr prior to the first blood sample.
Four of these patients were also tested on a separate occasion
without pretreatment. The test protocol was approved by the
local ethical and isotope committees, respectively.
Glomerular filtration rate measurements in this part of the
study were performed by the single injection method using
51Cr-EDTA and '251-sodium iothalamate. Ten microcuries of
'251-sodium iothalamate and 100 Ci 51Cr-EDTA were mixed
with 10 ml of physiological saline and given as a rapid intra-
venous injection. Venous blood samples (2 x 5 ml) were drawn
180, 210, and 240 mm after the injection. The 51Cr-EDTA and
'251-sodium iothalamate plasma clearances were calculated ac-
cording to the slope-intercept method described by BrØchner-
Mortensen [7]. The clearance values were corrected to 1.73 m2
body surface.
Isotope analysis
125! and 51Cr activities were determined in a two-channel
scintillation spectrometer. 14C or tritium activity was deter-
mined in 0.1 ml plasma and urine, respectively, added to 5 ml of
a toulene scintillation mixture with 6 vol % Bio-solv BBS3
(Beckman Instruments Inc., Fullerton, California, USA) using
a liquid scintillation spectrometer. Appropriate crossover cor-
rections were made for simultaneously determined isotopes
using a specially designed computer program.
Substances
125j sodium iothalamate, 51Cr EDTA (etylene-diamino tetra-
acetic acid), 14C PAH (paraminohippurate), and 3H-inulin were
obtained from the Radiochemical Centre, Amersham, England;
inulin from Loevosan Gesellschaft, Linz, Austria; iothalamate
(Conray) from Astra-Meditec, Molndal, Sweden; o-iodohip-
purate from Aldrich Chemical Co. Inc., Milwaukee, Wisconsin,
USA; iodipamide (Biligrafin Forte) from Schering AG, Berlin,
Germany; sodium novobiocin from Merck Sharp and Dohme,
Rahway, New Jersey, USA; and probenecid was prepared for
intravenous use in humans by Astra AB, Södertälje, Sweden.
Statistical analysis
Results are given as the arithmetic means SD or SEM.
Differences were analyzed statistically with Student's t test for
paired or unpaired observations and were considered significant
at the 0.05 level.
Results
Experiments with renal cortical slices
In all four species (chicken, rabbit, rat, and monkey) tested
the tissue-to-medium (TIM) ratio for 125J iothalamate was more
than twice those of 51Cr-EDTA at 37°C (Fig. 2). At 0°C,
however, the T/M ratio was equal for the two markers and not
different from that of 51Cr-EDTA at 37°C. Moreover, in the
presence of o-iodohippurate oriodipamide, inhibitors of organic
anion transport [4, 8], the T/M ratio for 125J iothalamate was
markedly depressed, approaching that of 51Cr-EDTA. Taken
together these results indicate an energy-dependent accumula-
tion of 125! iothalamate in renal cortical slices of chickens and
three mammalian species, probably reflecting organic anion
transport [9].
Experiments with the Sperber technique
Clearance experiments. The renal clearance of 125! iothalam-
ate in the contralateral kidney in the steady-state was about
twice that of the other markers, 51Cr-EDTA and 3H-inulin,
when simultaneously determined. The clearance values for the
latter markers did not differ (the small differences observed
were not statistically significant) and agreed with values found
in previous studies [10]. During coadministration of novobiocin,
an inhibitor of organic anion transport [8, 11], the renal clear-
ance values of 125J iothalamate were markedly reduced and
approached those of the other markers. Furthermore, during
control periods the apparent ipsilateral renal clearance values of
125! iothalamate were significantly higher than those on the
contralateral side—a difference that was markedly reduced
during novobiocin coadminstration (data not shown). Contrary
to this finding, the renal clearance values of 51Cr-EDTA and
3H-inulin were always equal for the two kidneys (data not
shown). These results show a significant active tubular secre-
tion of 125! iothalamate in the chicken kidney, probably involv-
ing an anion transport system. As shown in Figure 3, when a
new steady-state was reached during novobiocin coadministra-
tion, the mean renal clearance value for 125J iothalamate tended
to be lower than that of the other markers—for one such
clearance period even significantly so, possibly suggesting that
125J iothalamate is subject also to some degree of tubular
reabsorption in the chicken. During novobiocin coinfusion the
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Fig. 3. Renal clearance values for 125j jothalamate 51Cr-EDTA, and
3H-inulin (continuous infusion technique) in the contralateral kidney of
five hens before and during coadministration of novobiocin. Results are
given as mean values and 1 SD (vertical lines). Statistically significant
differences between 125J iothalamate and simultaneously determined
3H-inulin clearances are indicated: *<0.05; ** <0.02; *** < 0.01.Symbols are: •• 125J iothalamate; 0—0, 51Cr-EDTA; A—A,
3H-inulin.
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Fig. 4. Results from experiments with the Sperber technique in the
chicken. Apparent tubular excretion fraction (ATEF) values and total
urinary recovery (percentage of infused amount) of I25J iothalamate,
51Cr-EDTA (N = 20) and 125J (N = 4) in steady-state before (open
columns) and after (striped columns) coadministration of novobiocin
(100 mglkglhr). Results are given as mean values and I SD (vertical
lines). Statistically significant reduction by novobiocin is shown by **
<0.01.
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Fig. 2. Tissue to medium (T/M) ratios for Cr-EDTA
(filled columns) and /25J iothalamate (open columns) in
renal cortical slices from chicken, rabbits, rats, and
one cynomolgus monkey at 0° and 37°C without (ND)
and with inhibitors of organic anion transport.
Abbreviations are: HIPP, o-iodo-hippurate; BF,
iodipamide. Mean values of chicken (N = 2), rabbit(N = 2), and rat (N = 3) experiments are given.
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clearance values of 51Cr-EDTA and 3H-inulin still did not differ
from each other, but were 18% lower than during control
periods. This agrees with previous findings for 51Cr-EDTA 8J
and suggests that novobiocin slightly reduces glomerular filtra-
tion.
ATEF and urinary recovery studies (Fig. 4). The mean ATEF
value of 1251 iothalamate in steady-state was 0.08, a value
significantly different (P < 0.01) from that of 51Cr-EDTA (mean
ATEF, 0.01). During novobiocin coinfusion (new steady-state)
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Fig. 5. Renal extractions (%) of '4C paraaminohippurate (tilled col-
umns). 125j iothalamate (open columns) and 51Cr-EDTA (dotted col-
umns) in seven rats in steady-state before and after infusion of
probenecid (50 mglkg/hr). Results are given as mean values + 1 SCM.
Statistically significant reduction by probenecid is shown.
ATEF values for 1251 iothalamate and SlCrEDTA were equal
and averaged —0.01. Corresponding values for 1251 (infused as
the sodium salt in solution) were 0.03 and 0.01, respectively.
The mean total urinary recovery in the steady-state of 125j
iothalamate was 84% of the amount infused, a value which was
significantly reduced to 57% during novobiocin coinfusion. The
corresponding recoveries for 51Cr EDTA and 1251, respectively,
were not changed by novobiocin. Together these results sup-
port the concept that 125j iothalamate (but not 5'Cr-EDTA or
free 125!) is subject to active tubular secretion in the chicken
(compare with [12]).
Experiments with rats
The renal extraction of 51Cr-EDTA in the rat averaged 22%,
a value which was not changed during coadministration of
probenecid, an organic anion transport inhibitor [131. This
indicates that probenecid did not affect the GFR in the rat
kidney. As expected, probenecid reduced the 14C PAH extrac-
tion by 80% (Fig. 5). Moreover, the 1251 iothalamate extraction
was reduced by 41%, presumably by interference with its
tubular secretion. It is obvious in Figure 5 that some secretion
of PAH prevailed; it was not possible, however, to further
increase the dose of probenecid due to adverse effects (drop in
mean blood pressure). Furthermore, during probenecid treat-
ment the renal extraction of 125J iothalamate was 23% lowe
than that of 5'Cr-EDTA. Although this difference was not
statistically significant, it may suggest a tubular reabsorption of
125j iothalamate also in the rat kidney.
Study in healthy volunteers
The renal clearance of inulin (C1) in the steady-state aver-
aged 120 33.2 and 94 15.5 ml/min/l.73 m2 body surface
before and after the injection of probenecid, respectively
(means SD; all clearance values calculated from the average
of two to three clearance periods before and after probenecid in
each of six volunteers); a mean reduction of 21.7% (P < 0.05)
was found. This agrees with our earlier findings [14]. The
average renal clearance of unlabelled iothalamate (CloT) in
steady-state before probenecid was equal to that of creatinine
(Ccr) and exceeded that of inulin with 38% (P < 0.01 in both
cases, compare Fig. 6). It is well documented that the renal
clearance of creatinine will overestimate the true GFR due to
active tubular secretion of creatinine [9, 23]. Our results in
healthy volunteers strongly imply that this is the case also for
iothalamate. After probenecid, CloT and Ccr still significantly
exceeded C1 (Fig. 6). More importantly, probenecid reduced
CloT/Cl11 by 34% (P < 0.05) and CcrICin by 63% (NS) compared
to control ratios (Fig. 6). It seems therefore that the tubular
secretion of iothalamate in humans involves an organic anion
transport system.
Clinical study
The simultaneously determined plasma clearance values for
51Cr-EDTA and 125j iothalamate are presented in Table 1. Those
patients who had a unilateral nephrectomy are presented as
group 1, the others as group 2. Calculated on all patients, the
clearance values for 125J iothalamate were significantly higher
than those of 51Cr-EDTA (P <0.001). This was true for patients
with, as well as without, probenecid pretreatment. Without
pretreatment the plasma clearance of 125J iothalamate was on
the average 13% higher than that of 51Cr-EDTA. Probenecid
administration did not abolish the difference between the two
filtration estimates but reduced the difference significantly to an
average of 7% (P < 0.01). These results indicate that discrepan-
cies between 51Cr-EDTA and 1251 iothalamate clearance values
also in humans may depend on a tubular secretion of 125J
iothalamate. The fact that probenecid did not completely abol-
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Fig. 6. Percentage difference in steady-state renal clearance values(calculated as the average of three clearance periods in each of six
healthy volunteers) of iothalamate (CLOT) and creatinine (Ccr) com-
pared to that of inulin (C3) before (open columns) and after (filled
columns) probenecid injection. Results are shown as mean values + I
SCM. *P < 0.05 and ** < 0.01 denotes significant difference compared
to C1, and *** < 0.05 denotes significant reduction by probenecid.
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ish the difference between 51Cr-EDTA and 125! iothalamate
clearance values is possibly due to insufficient inhibition by
probenecid of tubular secretion; in a previous study in humans
it was found that a corresponding dosage of probenecid reduced
the average renal clearance of unlabeled PAH by only 17.4%
[141.
Discussion
The initial studies of the validity of iothalamate as a marker
for glomerular filtration were performed by Griep and Nelp [15].
In stop-flow studies in dogs they found that the urine to plasma
ratios for cobalt 57-labelled vitamin B12 parallelled those of 125j
iothalamate, and they concluded that there was no significant
tubular reabsorption nor secretion of iothalamate in this spe-
cies. Moreover, they found negligible urinary excretion of 131J
iothalamate in aglomerular fish over a 24-hr observation period
whereas 30% of the infused amount of phenol red was excreted.
Oester, Olesen, and Madsen [161 found a good correlation
between simultaneously determined renal clearances of inulin
and 125j iothalamate in dogs using a constant infusion technique.
Further studies in humans showed an excellent correlation
between the renal clearance of 125J or 1311-labelled iothalamate
and that of inulin, when iothalamate was administered as a
constant intravenous infusion [17—19] or subcutaneously [19], It
should be realized that an average renal clearance value of
iothalamate similar to that of inulin, is still compatible with a
tubular secretion of the former, if there is a simultaneous, and
quantitatively similar, tubular reabsorption. In such a case,
however, individual values would be expected to differ more. In
the study by Anderson, Sawyer, and Cutler [20], although an
acceptable overall correlation was found, there is a notable
scattering of simultaneously obtained clearance measurements
of 125J iothalamate and inulin. The same is true in the study of
Gagnon et al [21], especially in the patients with inulin clear-
ance values above 80 ml/min. This tendency was even more
pronounced in dogs, where the renal clearance of 125! iothalam-
ate was significantly lower than that of inulin; this was true
whether inulin was analyzed with the anthrone method or
according to Heyrovsky [21]. In the same study it was also
found that the renal extraction of 125J iothalamate in dogs was
lower than that of inulin, 0.37 versus 0.43%, respectively. Some
of our findings after transport inhibition in chickens (Fig. 3) and
rats (Fig. 5) are consistent with these results, and could be the
result of a small tubular reabsorption of 125J iothalamate in these
species. In the study of Gagnon eta! [21], however, the ratio of
1251 iothalamate to inulin clearance was not changed when
unlabelled iothalamate was added as a carrier, which was
considered as evidence against a tubular reabsorption of
iothalamate in dogs. Interestingly, Sigman et al [221 in their
earliest paper found the average 131J iothalamate renal clearance
value in humans to be about 10% higher than that of inulin
(continuous infusion technique). This result is comparable to
the 13% difference that we found for 1251 iothalamate versus
51Cr-EDTA plasma clearance in patients (Table 1). In healthy
volunteers, however, we found the renal clearance of unlabel-
led iothalamate to be on an average 38% higher than that of
inulin. It is at this time unclear whether this difference depends
on the subjects tested (patients vs. healthy volunteers), the
clearance method (plasma vs. renal clearance), the marker (125f
vs. unlabelled iothalamate) or on the reference marker (51Cr-
EDTA vs. inulin). It strongly indicates, however, that the
higher 125! iothalamate plasma clearance obtained in patients
compared to that of 51Cr-EDTA (Table 1) most likely reflects a
higher renal clearance, probably due to tubular secretion of 125j
iothalamate in these patients.
Of special interest in the present context are the findings by
Rosenbaum et al [23] that the renal clearance values for 125!
iothalamate (and creatinine) obtained in kidney donors and
transplant recipients were significantly higher than those of
inulin. Their conclusion was that inulin is inadequate as a
marker for glomerular filtration in these subjects. An alternative
explanation, and a more likely one in view of our results, is that
their results reflect a tubular secretion of 1251 iothalamate and
therefore incriminates this substance rather than inulin as a
marker for glomerular filtration. In support of this, it is well
known that creatinine which in our study (Fig. 6) as well as in
the study of Rosenbaum et al [23] gave similar renal clearance
values as (125!) iothalamate, is clearly subject to tubular secre-
tion in humans [9].
It is apparent from our clearance data that the renal tubular
secretion was more pronounced in the chicken as compared to
the mammalian species. This may reflect the difference in
filtration fraction (GFRIRPF) in the three species which is about
10, 28, and 21% in chicken [241, rats [25], and humans,
respectively. In other words, a tubular secretion of a substance
is more readily detected in a species such as the chicken with a
relatively low GFR, all other factors being equal. Considering
also other advantages with the Sperber technique (compare
[24]), it seems warranted to recommend a wider use of this
technique in studies of the renal handling of organic substances,
especially concerning their renal tubular secretion.
It may seem that the difference found in our patients between
the plasma clearance of 125J iothalamate and that of 51Cr-EDTA
is clinically unimportant. However, in some patients (compare
patients 3 and 13 in Table 1) the difference is marked. Further-
more, it is well known that creatinine clearance tends to
overestimate the GFR especially in patients with renal in-
sufficiency presumably due to increased tubular secretion of
this substance (compare [26]). Although it has not yet been
tested, it is reasonable to assume that this may also apply to
iothalamate, a substance that evidently also is subject to tubular
secretion in humans. Moreover, the common clinical practice to
determine glomerular filtration by the so-called single injection
technique, where the clearance values are calculated from the
elimination curve of the test substance in blood, may be
unnecessarily complicated by the use of an inadequate marker
[271. For instance, in the extensive study of Hall, Guyton, and
Farr [28] the renal clearance of inulin was related to the plasma
clearance of 1251 iothalamate, as calculated by different
formulae. The correlation was bad when using a slope intercept
method for calculation of the plasma clearance of iothalamate;
it was better when using a two-compartment model, while it
was acceptable by using a method based on the total area under
the plasma concentration time curve. This reasoning is based on
the assumption that iothalamate is an ideal marker for glomer-
ular filtration. Our results do not support this assumption.
lothalamate and its isomers diatrizoate and iodamide (com-
pare Fig. 1) are all derived from 2, 4, 6 triiodobenzoic acid; from
a structural point of view, one would expect them to be subject
to some degree of renal tubular secretion. Indeed, a renal
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tubular secretion has been demonstrated in several mammalian
species for diatrizoate [29, 30] and for iodamide [31—33]. Fur-
thermore, it is well known that iothalamate [34, 351 and diatrizo-
ate [34—36] significantly reduce the renal extraction of PAH in
dogs and humans. Moreover, diatrizoate inhibits the accumula-
tion of PAH in renal cortical slices [371.These effects are most
probably due to competitive inhibition of organic anion trans-
port in the tubules and supports the idea of a tubular secretion
of iothalamate and diatrizote.
Angiographic contrast media such as iothalamate and
diatrizoate are potentially nephrotoxic [38] and occasionally
produce acute renal failure [39]. The pathogenesis of contrast
media-induced acute renal failure is unclear; renal ischemia,
intraluminal obstruction, and direct toxic effects on tubular
cells have been postulated as possible causes [401. A tubular
secretion of these contrast agents—and associated accumula-
tion in proximal (?) tubular cells [9, 371—creates the possibility
of an intracellular mechanism behind the nephrotoxicity, per-
haps similar to that of the cephalosporins [41].
Finally, an active tubular transport of the contrast medium
may contribute to the appearance of a normal nephrogram
during infusion urography in many patients with early oliguric
renal failure [42]. This has been postulated to reflect persistent
glomerular filtration and subsequent backleak of contrast mol-
ecules [42]. An alternative explanation is that the nephrogram
appears normal because of active transport of contrast media
from peritubular blood into (proximal?) tubular cells and still
not obstructed tubular lumina.
In conclusion, results in the present study unequivocally
show a marked tubular secretion of 125J iothalamate in chickens
and rats. It seems therefore that this substance is not a suitable
marker for glomerular filtration in experimental studies. Fur-
thermore, our results indicate a significant and sometimes
marked tubular secretion of iothalamate in humans, giving
plasma (1251 iothalamate) and particularly renal (iothalamate)
clearance values that overestimate the true GFR. 1251 iothalam-
ate, therefore, does not seem to be an ideal reference substance
for determinations of glomerular filtration in clinical studies [23,
43, 44]. However, for clinical routine purposes 1251 iothalamate
may be used as a filtration marker with an apparent accuracy
comparable to that of creatinine.
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